Physician profile
Caroline M Morrison
NPI 1285707935
$43,781.20
in general payments reported to CMS, 2019-2025
24 companies · $7,632 in 2025
The $7,632 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $4,018 · 2021: $1,964 · 2022: $342 · 2023: $18K · 2024: $11K · 2025: $7,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Consulting Fee: $4,630 · Travel and Lodging: $2,590 · Food and Beverage: $2,369 · Education: $7.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,455.00 |
| Consulting Fee | $4,630.00 |
| Travel and Lodging | $2,589.64 |
| Food and Beverage | $2,369.35 |
| Education | $7.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $35,928.47 | 2021-2025 | Lybalvi, Aristada |
| Allergan, INC. | $3,970.92 | 2020 | |
| Abbvie INC. | $2,158.31 | 2021-2025 | |
| Lilly USA, LLC | $270.71 | 2023-2025 | Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $176.71 | 2019-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $172.27 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $140.58 | 2021-2025 | Caplyta |
| Lundbeck LLC | $132.94 | 2019-2024 | Rexulti |
| Vivus LLC | $124.97 | 2023 | Qsymia |
| Sunovion Pharmaceuticals INC. | $88.13 | 2019 | |
| Corium, LLC | $86.17 | 2022-2025 | Azstarys |
| Novo Nordisk INC | $84.09 | 2025 | Ozempic, Wegovy, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $69.59 | 2019-2024 | Trintellix |
| Avanir Pharmaceuticals, INC. | $64.55 | 2019 | |
| Axsome Therapeutics, INC. | $64.19 | 2022-2023 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $54.12 | 2019-2024 | Fanapt |
| Neurocrine Biosciences, INC. | $53.04 | 2019-2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $36.66 | 2023-2024 | Quviviq |
| Bausch Health US, LLC | $33.90 | 2020-2021 | |
| Itamar Medical INC | $18.90 | 2025 | Watchpatone |
| Biogen, INC. | $15.00 | 2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $13.72 | 2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $12.30 | 2022 | |
| Ironshore Pharmaceuticals INC. | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.